Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F E Ali

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|October 16, 1992
Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptidesC E Peishoff, F E Ali, J W Bean, et al.
Journal of Medicinal Chemistry|March 18, 1994
Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregationF E Ali, D B Bennett, R R Calvo, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonistW E Bondinell, R M Keenan, W H Miller, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 1998
Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptidesA Wong, S M Hwang, K Johanson, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, M A Lago, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis modelR M Keenan, M A Lago, W H Miller, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|October 16, 1992
Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptidesC E Peishoff, F E Ali, J W Bean, et al.
Journal of Medicinal Chemistry|March 18, 1994
Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregationF E Ali, D B Bennett, R R Calvo, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonistW E Bondinell, R M Keenan, W H Miller, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 1998
Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptidesA Wong, S M Hwang, K Johanson, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, M A Lago, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis modelR M Keenan, M A Lago, W H Miller, et al.
Pageof 2